ArticleTherapeutic advances in medical oncology2026
Impact of hepatic radiotherapy on survival and safety outcomes in small cell lung cancer patients with liver metastases: a retrospective study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with extensive-stage small cell lung cancer (ES-SCLC) and liver metastases (LM) are known to have particularly poor clinical outcomes, creating a significant therapeutic dilemma regarding optimal management of hepatic metastases beyond conventional systemic therapies. Objectives: This study sought to investigate the impact of adding LM-directed radiotherapy to systemic therapy on survival outcomes and treatment-related adverse events in patients with ES-SCLC and liver metastases. Design: This retrospective study enrolled ES-SCLC patients with LM treated at our institution between January 2019 and March 2025, all of whom received at least one cycle of systemic therapy. Patients were grouped by whether they received LM‑directed radiotherapy after LM diagnosis. Methods: Propensity score matching (PSM) was used to balance baseline characteristics between patients in the two groups. Kaplan-Meier survival curves were plotted to estimate survival endpoints. Treatment-related adverse events were graded per Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Results: After PSM, a total of 495 patients were analyzed, among whom 138 underwent LM-directed radiotherapy. After a median follow-up of 38.1 months, patients in the radiotherapy group had a median overall survival (OS) of 12.1 months, significantly longer than the 6.7 months observed in the nonradiotherapy group (hazard ratios (HR), 0.51; 95% confidence intervals (CI): 0.41-0.63; Conclusion: In patients with ES-SCLC and LM, the addition of LM-directed radiotherapy to systemic therapy provides a significant survival benefit with acceptable treatment-related toxicity. These findings suggest that LM-directed radiotherapy can serve as a safe and effective treatment option for this patient population with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.